Macular Degeneration News and Research

Latest Macular Degeneration News and Research

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

ACT files IND application to initiate Phase I/II study for Dry AMD

Advanced Cell Technology, Inc. announced today that it has filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using human embryonic stem cell (hESC) derived retinal pigment epithelial (RPE) cells to treat patients with Dry Age-Related Macular Degeneration (Dry AMD).

30 Nov 2010

QOI and Quantel enter co-promotion agreement for Activis PDT Lasers

QLT Inc. today announced that its wholly-owned U.S. subsidiary, QLT Ophthalmics, Inc. ("QOI"), and Quantel Medical and its distributor, Quantel USA, Inc., have entered into a co-promotion agreement for the sale of Activis PDT Lasers used to activate Visudyne® during photodynamic therapy of primarily classic lesions in wet age-related macular degeneration (AMD). The lasers are manufactured by Quantel Medical and sold by Quantel USA, Inc. and will be promoted by both Quantel USA, Inc. and QOI's sales force to the retina community in the United States.

29 Nov 2010

BioTime, CIRM enter agreement for GMP-grade hES cell lines

BioTime, Inc. today announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human embryonic stem (hES) cell lines available to California-based researchers. CIRM is the stem cell agency created when California voters supported a $3 billion funding measure for stem cell-related research and clinical translation.

29 Nov 2010

Los Angeles philanthropist foundation model to commercialize research at Ben-Gurion University

A Los Angeles philanthropist has created an innovative foundation model that will provide up to $1.2 million to help fund and commercialize research at Ben-Gurion University of the Negev in Beer-Sheva, Israel.

24 Nov 2010

NIH expands genetic and clinical research database to provide access to digital study images

The National Institutes of Health has expanded a genetic and clinical research database to give researchers access to the first digital study images.

24 Nov 2010

Stem cell trial for eye disease receives FDA approval

The second clinical trial involving stem cells from human embryonic cells has received the go-ahead. The news came from Advanced Cell Technology Inc. this Monday. The company announced that the U.S. Food and Drug Administration has cleared the way for its Phase I/II trial of retinal cells for patients with Stargardt’s macular dystrophy, a childhood version of macular degeneration.

22 Nov 2010

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.

22 Nov 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

Chardan initiates independent equity research coverage on StemCells

StemCells, Inc. announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.

From Baxter International Inc. 19 Nov 2010

Krieger Eye Institute at Sinai Hospital opens new center for treatment of retinal diseases

The Krieger Eye Institute at Sinai Hospital opened a new center for the treatment of retinal diseases in November. The retina is the layer of tissue at the back of the eye that converts images to electrical impulses. These electrical signals are then perceived by the brain as sight.

18 Nov 2010

Popular Science names VisionCare's Implantable Miniature Telescope for AMD 'Best of What's New' 2010

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices, today announced the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), designed to improve vision in patients with end-stage age-related macular degeneration (AMD) is named "Best of What's New" 2010 by Popular Science magazine.

17 Nov 2010

BioTime third quarter total revenues increase 82% to $815,284

BioTime, Inc. today reported financial results for the quarter ended September 30, 2010 and provided an update on recent corporate developments.

15 Nov 2010

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.

15 Nov 2010

Adeona third quarter total net revenues increase to $289,898

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced its third quarter 2010 financial results as well as recent clinical and operational achievements.

15 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours.

9 Nov 2010

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

ACT files IND application to initiate Phase I/II study for Dry AMD

QOI and Quantel enter co-promotion agreement for Activis PDT Lasers

BioTime, CIRM enter agreement for GMP-grade hES cell lines

Los Angeles philanthropist foundation model to commercialize research at Ben-Gurion University

NIH expands genetic and clinical research database to provide access to digital study images

Stem cell trial for eye disease receives FDA approval

FDA grants ACT clearance for Phase I/II clinical trial of hESC derived retinal cells in patients with SMD

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Chardan initiates independent equity research coverage on StemCells

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Krieger Eye Institute at Sinai Hospital opens new center for treatment of retinal diseases

Popular Science names VisionCare's Implantable Miniature Telescope for AMD 'Best of What's New' 2010

BioTime third quarter total revenues increase 82% to $815,284

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

Adeona third quarter total net revenues increase to $289,898

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in